Affiliation:
1. Department of Oral Medicine, Pathology & Immunology, GKT Dental Institute, Kings College London, London, United Kingdom
2. Robert Koch Institut, D-13353 Berlin, Germany
Abstract
SUMMARY
Candida albicans is the most common fungal pathogen of humans and has developed an extensive repertoire of putative virulence mechanisms that allows successful colonization and infection of the host under suitable predisposing conditions. Extracellular proteolytic activity plays a central role in Candida pathogenicity and is produced by a family of 10 secreted aspartyl proteinases (Sap proteins). Although the consequences of proteinase secretion during human infections is not precisely known, in vitro, animal, and human studies have implicated the proteinases in C. albicans virulence in one of the following seven ways: (i) correlation between Sap production in vitro and Candida virulence, (ii) degradation of human proteins and structural analysis in determining Sap substrate specificity, (iii) association of Sap production with other virulence processes of C. albicans, (iv) Sap protein production and Sap immune responses in animal and human infections, (v) SAP gene expression during Candida infections, (vi) modulation of C. albicans virulence by aspartyl proteinase inhibitors, and (vii) the use of SAP-disrupted mutants to analyze C. albicans virulence. Sap proteins fulfill a number of specialized functions during the infective process, which include the simple role of digesting molecules for nutrient acquisition, digesting or distorting host cell membranes to facilitate adhesion and tissue invasion, and digesting cells and molecules of the host immune system to avoid or resist antimicrobial attack by the host. We have critically discussed the data relevant to each of these seven criteria, with specific emphasis on how this proteinase family could contribute to Candida virulence and pathogenesis.
Publisher
American Society for Microbiology
Subject
Molecular Biology,Microbiology,Infectious Diseases
Reference261 articles.
1. Abad-Zapatero, C., R. Goldman, S. W. Muchmore, C. Hutchins, K. Stewart, J. Navaza, C. D. Payne, and T. L. Ray. 1996. Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Protein Sci.5:640-652.
2. Abu-Elteen, K. H., A. Z. Elkarmi, and M. Hamad. 2001. Characterization of phenotype-based pathogenic determinants of various Candida albicans strains in Jordan. Jpn. J. Infect. Dis.54:229-236.
3. Acosta, E. P., T. N. Kakuda, R. C. Brundage, P. L. Anderson, and C. V. Fletcher. 2000. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin. Infect. Dis.30(Suppl. 2):S151-S159.
4. Agatensi, L., F. Franchi, F. Mondello, R. L. Bevilacqua, T. Ceddia, F. De Bernardis, and A. Cassone. 1991. Vaginopathic and proteolytic Candida species in outpatients attending a gynaecology clinic. J. Clin. Pathol.44:826-830.
5. Apodaca, G., and J. H. McKerrow. 1990. Expression of proteolytic activity by cultures of Trichophyton rubrum.J. Med. Vet. Mycol.28:159-171.
Cited by
924 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献